<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Patiromer: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Patiromer: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Patiromer: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="104961" href="/d/html/104961.html" rel="external">see "Patiromer: Drug information"</a> and <a class="drug drug_patient" data-topicid="105351" href="/d/html/105351.html" rel="external">see "Patiromer: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F45755745"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Veltassa</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F53996270"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Veltassa</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F54153321"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote</span>;</li>
<li>
<span class="list-set-name">Potassium Binder</span></li></ul></div>
<div class="block dop drugH1Div" id="F58819064"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b5810b4-b874-43a4-be72-5d6c74de492e">Hyperkalemia, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia, chronic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: Initial: 4 g once daily; adjust dose at weekly intervals (or longer) in 4 g/day increments based on serum potassium levels; maximum daily dose: 25.2 g/<b>day</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F58819143"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;">No dosage adjustment necessary.</p></div>
<div class="block dohp drugH1Div" id="F58819144"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F45780978"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="104961" href="/d/html/104961.html" rel="external">see "Patiromer: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b5810b4-b874-43a4-be72-5d6c74de492e">Hyperkalemia, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia, chronic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 8.4 g once daily; adjust dose by 8.4 g daily at ≥1-week intervals, as needed, based on serum potassium levels; maximum dose: 25.2 g/day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991256"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (no systemic absorption) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed: No supplemental dose or dosage adjustment necessary (no systemic absorption) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-30775627']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-30775627'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed: No dosage adjustment necessary (no systemic absorption) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988535"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F45499976"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (5%), hypomagnesemia (5% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (2%), constipation (7%), diarrhea (5%), flatulence (2%), nausea (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Gastrointestinal: Vomiting</p></div>
<div class="block coi drugH1Div" id="F45486654"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to patiromer or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hereditary condition of fructose intolerance (eg, sorbitol).</p></div>
<div class="block war drugH1Div" id="F45780968"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• GI effects: Avoid use in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders; patiromer may be ineffective and may worsen GI conditions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypomagnesemia: Patiromer binds to magnesium in the colon, which can lead to hypomagnesemia. Monitor serum magnesium and consider magnesium supplementation if hypomagnesemia develops.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: May experience more gastrointestinal adverse reactions.</p></div>
<div class="block prod-avail drugH1Div" id="F58737324"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Veltassa 1 g packets: FDA approved October 2023; anticipated availability currently unknown. Veltassa 1 g packets are intended for use in pediatric patients 12 years and older. Consult the prescribing information for additional information.</p></div>
<div class="block foc drugH1Div" id="F45755746"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Veltassa: 8.4 g (1 ea, 4 ea, 30 ea); 16.8 g (1 ea, 30 ea); 25.2 g (1 ea, 30 ea)</p></div>
<div class="block geq drugH1Div" id="F45755744"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F46105217"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Veltassa Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8.4 g (per each): $54.77</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">16.8 g (per each): $40.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25.2 g (per each): $40.99</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F53996271"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Veltassa: 8.4 g (8.4 g); 16.8 g (30 ea)</p></div>
<div class="block admp drugH1Div" id="F58819076"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to food. Do not administer patiromer in its dry form; requires mixing with liquid or soft food and immediate consumption. According to the manufacturer, all medications except those that have been identified as not having a clinically important interaction with patiromer should be administered at least 3 hours before or 3 hours after patiromer (consult drug interactions database for more information). Do not heat patiromer (eg, microwave) or add to heated foods or liquids.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Mixing with liquid: </i>Immediately prior to administration, measure <sup>1</sup>/<sub>3</sub> cup (~80 mL) of water (or other beverage) and pour half into an empty glass; empty entire contents of the packet(s) into the glass and stir thoroughly (powder will not dissolve and the mixture will look cloudy). Add remaining half of water and mix well; may add more water (or other beverage) to mixture until desired consistency and mix well. If powder remains in the glass after drinking, add more water, stir, and drink immediately; repeat as needed to ensure the entire dose is administered.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Mixing</i>
<i> with soft food (eg, applesauce, yogurt, pudding):</i> A minimum of 45 mL (3 tablespoons) of soft food will be needed to prepare a dose up to 4 g. Immediately prior to administration, place half of desired amount of soft food into a container, add up to 4 g of patiromer from packet(s), and mix well. Add remaining amount of soft food and mix well; may add more soft food until desired consistency and mix well.</p></div>
<div class="block adm drugH1Div" id="F45780984"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer without regard to food. Do not administer patiromer in its dry form. Following reconstitution, drink mixture immediately. If powder remains in the glass after drinking, add more water, stir, and drink immediately; repeat as needed to ensure the entire dose is administered. Other beverages or soft foods (eg, apple sauce, yogurt, pudding) may be used for preparation and administration instead of water. Do not heat patiromer (eg, microwave) or add to heated foods or liquids. According to the manufacturer, all medications except those that have been identified as not having a clinically important interaction with patiromer should be administered at least 3 hours before or 3 hours after patiromer (consult drug interactions database for more information).</p></div>
<div class="block sts drugH1Div" id="F45780970"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store  at 2°C to 8°C (36°F to 46°F). If stored at room temperature (25°C ± 2°C [77°F ± 4°F]), use within 3 months of being taken out of the refrigerator. Avoid exposure to excessive heat above 40°C (104°F). </p></div>
<div class="block usep drugH1Div" id="F58819063"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of hyperkalemia (FDA approved in ages ≥12 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Patiromer should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.</p></div>
<div class="block cyt drugH1Div" id="F45525292"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F45525289"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bisoprolol: Patiromer may decrease the serum concentration of Bisoprolol.  Management: Administer bisoprolol at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carvedilol: Patiromer may decrease the serum concentration of Carvedilol.  Management: Administer carvedilol at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin (Systemic): Patiromer may decrease the serum concentration of Ciprofloxacin (Systemic).  Management: Administer oral ciprofloxacin at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: Patiromer may decrease the serum concentration of Levothyroxine.  Management: Administer oral levothyroxine at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: Patiromer may decrease the serum concentration of MetFORMIN.  Management: Administer metformin at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Patiromer may decrease the serum concentration of Mycophenolate.  Management: Administer mycophenolate at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nebivolol: Patiromer may decrease the serum concentration of Nebivolol.  Management: Administer nebivolol at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: Patiromer may decrease the serum concentration of QuiNIDine.  Management: Administer quinidine at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Telmisartan: Patiromer may decrease the serum concentration of Telmisartan.  Management: Administer telmisartan at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiamine: Patiromer may decrease the serum concentration of Thiamine.  Management: Administer oral thiamine at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block dic drugH1Div" id="F56556449"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Consider the potassium content of the liquids or soft food used to prepare the mixture as part of the patient's dietary potassium recommendations.</p></div>
<div class="block pri drugH1Div" id="F45780966"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Patiromer is not absorbed systemically following oral administration. Use during pregnancy is not expected to result in significant exposure to the fetus.</p></div>
<div class="block mopp drugH1Div" id="F58819077"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum potassium and magnesium; stool output.</p></div>
<div class="block pha drugH1Div" id="F45780972"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Patiromer, a non-absorbed, cation exchange polymer that contains a calcium-sorbitol counterion, increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract, resulting in a reduction of serum potassium levels.</p></div>
<div class="block phk drugH1Div" id="F45780974"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 7 hours (Bushinsky 2015)</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of action: 24 hours (Bushinsky 2015)</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Not systemically absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (unchanged)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F50977943"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Patermer</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Veltassa</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26376130">
<a name="26376130"></a>Bushinsky DA, Williams GH, Pitt B, et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. <i>Kidney Int</i>. 2015;88(6):1427-1433. doi: 10.1038/ki.2015.270.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/patiromer-pediatric-drug-information/abstract-text/26376130/pubmed" id="26376130" target="_blank">26376130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26765867">
<a name="26765867"></a>Chaitman M, Dixit D, Bridgeman MB. Potassium-binding agents for the clinical management of hyperkalemia. <i>P T.</i> 2016;41(1):43-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/patiromer-pediatric-drug-information/abstract-text/26765867/pubmed" id="26765867" target="_blank">26765867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30775627">
<a name="30775627"></a>Kovesdy CP, Rowan CG, Conrad A, et al. Real-world evaluation of patiromer for the treatment of hyperkalemia in hemodialysis patients. <i>Kidney Int Rep</i>. 2018;4(2):301-309. doi:10.1016/j.ekir.2018.10.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/patiromer-pediatric-drug-information/abstract-text/30775627/pubmed" id="30775627" target="_blank">30775627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference">
                  US Food and Drug Administration. Clinical Pharmacology/Biopharmaceutics Review. Question Based Review (QBR): Patiromer (RLY5016). Published 2015.</div>
</li>
<li>
<div class="reference">
                  Veltassa (patiromer) [prescribing information]. Redwood City, CA: Vifor Pharma Inc; October 2023.</div>
</li>
<li>
<div class="reference">
                  Veltassa (patiromer) [product monograph]. Saint-Laurent, Quebec, Canada: Otsuka Canada Pharmaceutical Inc; February 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 143556 Version 4.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
